SLS Stock: Price, Earnings History and SEC Filings
SELLAS Life Sciences Group, Inc. (SLS) last traded at $9.68, down 4.72% on the latest session and down 21.4% over the past month.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SLS earnings history
Earnings history is not available right now.
How SLS reacts to earnings
Across its last 8 earnings releases, SLS moved 8.0% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | After close | +6.52% |
| 2026-07-27 | After close | -6.92% |
| 2026-05-12 | After close | +25.10% |
| 2026-03-19 | After close | -8.46% |
| 2026-01-08 | Before open | -4.46% |
| 2025-11-12 | After close | -2.01% |
| 2025-08-12 | After close | -3.73% |
| 2025-05-13 | After close | +7.09% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SLS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2023 | $0 | -$37M | – | – | $-1.34 |
| 2022 | $1M | -$41M | – | -4130.1% | $-2.13 |
| 2021 | $8M | -$21M | – | -272.4% | $-1.34 |
| 2020 | $2M | -$17M | – | -881.9% | $-2.11 |
| 2019 | $0 | -$19M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SLS
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Jul 27, 2026Results of operations, Other events, Financial statements and exhibits
- 8-K · Jun 25, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 18, 2026Shareholder vote
- 8-K · Jun 2, 2026Other events, Financial statements and exhibits
- 8-K · May 12, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 12, 2026
- DEF 14A · Apr 23, 2026
- 8-K · Mar 19, 2026Results of operations, Financial statements and exhibits
Insider filing activity
SLS insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SLS news
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Oct 30, 2026 · stocktwits.com
- SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?Oct 29, 2026 · finance.yahoo.com
- SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?Oct 29, 2026 · stocktwits.com
- Sellas’ GPS Trial Records 80th Event — Retail Says ‘Completely Irrational Sell Off’ As SLS Stock Tanks 18%Oct 28, 2026 · stocktwits.com
- Sellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final DataOct 28, 2026 · tikr.com
- SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid LeukemiaOct 28, 2026 · finance.yahoo.com
- SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval ForecastOct 28, 2026 · stocktwits.com
- SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 YearsOct 20, 2026 · stocktwits.com
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (SLS) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.